| Ytd | -0.51% | |
| 1y | -0.13% |
| Open | 59.50 | Prev Close | 59.21 | Low | 59.20 | High | 59.98 | Mkt Cap | 11.44B |
| Vol | 502.05K | Avg Vol | 2.04M | EPS | 2.08 | P/E | 28.47 | Forward P/E | 11.89 |
| Beta | 0.24 | Short Ratio | 6.29 | Inst. Own | 102.17% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-03 | 50-d Avg | 56.01 | 200-d Avg | 56.06 | 1yr Est | 87.69 |
BMRN News
BioMarin: Commercial Infrastructure Is The Hidden Growth Asset
D.A. Davidson and CO. boosted its holdings in shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
Citigroup analyst Eric Joseph maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Buy and rais
BioMarin's FDA filing for full Voxzogo approval in achondroplasia has been accepted, with a regulato
The sNDA submission was supported by substantial long-term safety and efficacy data from three ongoi
Application based on long-term safety and efficacy data from three ongoing studies, including adult
RBC Capital analyst Luca Issi maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Sector Perfo
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investi
Data from an investigator-led study showed treatment with VOXZOGO resulted in sustained improvements
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock?
BMRN's shares rise after Voxzogo hits the main goal in a late-stage hypochondroplasia study, support
BioMarin Pharmaceuticals Inc. (NASDAQ:BMRN) stock is trading higher on Thursday as the company is ce
BioMarin Pharmaceutical said on Wednesday its treatment for a rare condition that leads to short st
Study met primary endpoint, exceeding expectations with a highly statistically significant improveme
BioMarin shares fall after BMN 401 meets a biomarker goal but misses a key radiographic endpoint in
Pre-Market Stock Futures: Futures are trading lower on Tuesday as the sell-off in technology stocks
BioMarin Pharmaceutical said on Monday its experimental treatment for a rare genetic condition met
ENERGY 3 study met 1 of 2 co-primary endpoints in children with ENPP1 deficiency Treatment with BMN
Pre-Market Stock Futures: Futures are trading mixed as we get set to start the new trading week, as
BioMarin Pharmaceutical remains a "Strong Buy," driven by pipeline progress, strategic acquisitions,
BMRN misses Q1 EPS estimates despite a revenue beat, as charges and higher costs weigh on profits, w
BioMarin Pharmaceutical Inc. (BMRN) Q1 2026 Earnings Call Transcript
Although the revenue and EPS for BioMarin (BMRN) give a sense of how its business performed in the q
Opportunity to buy undervalued health care stocks. RSI is a momentum indicator that compares strengt
Top Wall Street analysts changed their outlook on top names. See all changes on analyst ratings page
BridgeBio stock rises after Phase 3 trial shows its drug helped children with achondroplasia grow fa
US stocks edged higher midday Wednesday after strong Q3 GDP data. In commodities, both silver and go
Companies Reporting Before The Bell • Keurig Dr Pepper (NASDAQ:KDP) is projected to report quarterl
Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings
Companies Reporting Before The Bell • Immunogen (NASDAQ:IMGN) is estimated to report quarterly loss
On CNBC’s "Mad Money Lightning Round," Jim Cramer recommended holding Biomarin Pharmaceutica
Companies Reporting Before The Bell • Fresh Del Monte Produce (NYSE:FDP) is likely to report qua
During Monday's trading, 1214 companies set new 52-week lows.